Walleye Capital
ICPT

Walleye Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Walleye Capital’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-18,900
Closed -$2.34M – 1861
2019
Q4 		$2.34M Sell
18,900
-19,400
-51% -$1.74M 0.15% 161
2019
Q3 		$2.54M Buy
+38,300
New +$2.57M 0.15% 162

Other funds holding ICPT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Walleye Capital's ICPT Position: Q3 2022 in Review

Walleye Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2022, closing a stake of 22,600 shares — an estimated $312K sold.

Walleye Capital first reported a position in ICPT in Q4 2019 and held it in 6 quarters. The position peaked at $560K in Q3 2020. 156 funds tracked by Wall St. Rank hold ICPT as of Q3 2022.

  • Walleye Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • Walleye Capital sold 22,600 Intercept Pharmaceuticals, Inc. shares in Q3 2022, an estimated $312K.
  • Walleye Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2019 and held it in 6 quarters.
  • Walleye Capital's Intercept Pharmaceuticals, Inc. position peaked at $560K in Q3 2020.
  • 156 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2022.

Based on Walleye Capital's 13F filing for Q3 2022, filed 14 Nov 2022.